Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

NCT03403036 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Brodalumab

Sponsor

Icahn School of Medicine at Mount Sinai